TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06708702
Drug: Placebo mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be used, under the formula of liquid mint flavor 5%, Nipagim 0.1%, and distilled water qsp 60 ml, packed in packaging compatible with that of the product under investigation, maintaining the same physical characteristics to maintain blinding. The product will be stored at room temperature and stored in the INCA pharmacy.~Patients will receive the solution once a week. They will be instructed to shake the bottle before use for homogenization, to use 10mL of the solution for each mouthwash (which should be measured in the 10mL measuring cup that comes with each bottle), 4 times a day, rinsing vigorously for 1 minute and discarding all the solution after use.
Study: NCT06053398
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative norepinephrine infusion Norepinephrine infusion to be titrated as needed to target a MAP \> 65 mm Hg.
Study: NCT06708260
Drug: ENN0403, low dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: ENN0403 capsules will be orally administered once a day for 12 weeks.
Study: NCT06708260
Drug: ENN0403, high dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: ENN0403 capsules will be orally administered once a day for 12 weeks.
Study: NCT06176040
Drug: TAVO101
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAVO101 IV Infusion.
Study: NCT06708663
Drug: HX009+IN10018
Approvals — FDA: no, EMA: no, PMDA: no
Description: The 7.5 mg/kg dose group will first enroll 3 to 6 subjects, and if the 7.5 mg/kg dose group is tolerable, then 3 to 6 subjects will continue to be enrolled into the 10 mg/kg dose group; if the 7.5 mg/kg dose group is not tolerable, a decision will be made to add a new, lower dose group after discussion between the sponsor and the investigator; in addition, based on the available study data, the sponsor and the investigator will discuss and decide whether to add an unplanned dose group or an exploratory group and decide on the appropriate recommended dose (RP2D) for the Phase IIa study.~IN10018 is fixed dose at 100mg daily.
Study: NCT06712641
Drug: Gentamicin + narrow spectrum betalactam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical therapy for suspected community-acquired sepsis with gentamicin + narrow spectrum betalactam (either one of penicillin, ampicillin, or cloxacillin)
Study: NCT06300970
Drug: Artemether+Lumefantrine (AL)
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral medication given for treatment of uncomplicated plasmodium falciparum infection.
Study: NCT03693287
Drug: Standardized-parenteral nutrition (S-PN)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NUMETA G13%E 300 mL is a triple-chamber (lipid emulsion, amino acids solution with electrolytes, and glucose solution), ready-to-use parenteral nutrition product available to treat preterm infants (less than 37 weeks gestational age).
Study: NCT03693287
Drug: Personalized-parenteral nutrition (P-PN)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glucose will be dextrose 50%, amino acids (AA) will be Primene® and lipids (FAT) will be Clinoleic®.~Parenteral nutrition bags will be prepared by the hospital pharmacy according to the prescription of the attending neonatologist.
Study: NCT06504082
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: After confirming the diagnosis of tubal ectopic pregnancy, each patient will receive a single dose of intramuscular MTX (50 mg/m² MTX) on the same day
Study: NCT06710847
Drug: GSK4418959
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK4418959 will be administered.
Study: NCT06707987
Drug: Non-immunogenic staphylokinase
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: non-immunogenic staphylokinase 10 mg as a single intravenous bolus Other Names: Fortelyzin®
Study: NCT06353269
Drug: Estrace 0.01% Vaginal Cream
Normalized name: Estrace 0.01% Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: vaginal estrogen cream, used twice per week
Study: NCT06712888
Drug: GP plus placebo induction therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Placebo 240mg will be given every 3 weeks for 3 cycles, started on day 1 of induction chemotherapy.~Drug: Gemcitabine 1000mg/m2, d1 \& 8 of every cycle, every 3 weeks for 3 cycles before radiation.~Drug: Cisplatin Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation; Concurrent cisplatin 100mg/m2, every 3 weeks for 3 cycles during radiation~Other Names:~DDP Radiation: intensity-modulated radiotherapy Definitive intensity-modulated radiotherapy (IMRT) of 70 Gy will be given in 33 fractions.~Other Names:~IMRT
Study: NCT06712407
Drug: TARPEYO®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-months of TARPEYO® 16 mg QD then 9-month Treatment Period with TARPEYO® 8 mg QD and TARPEYO®4 mg QD for 2 weeks for tapering.
Study: NCT04832009
Drug: Dextrose 20 % in 500 ML Injection
Normalized name: dextrose 20 % in 500 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose (20% intravenous solution) will be obtained from the Investigational Pharmacy located in the KU Clinical Research Center where studies take place. After fasting for at least 8 hours, dextrose will be administered via antecubital vein at a standard rate of 4 mg/kg/min for 2 hours.
Study: NCT04832009
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: (ASCOR) will be obtained from the KU Investigational Pharmacy located in the KU Clinical Research Center where studies will take place. A priming bolus of 0.06 g ascorbic acid/kg fat free mass (FFM) dissolved in 100 mL of saline will be infused intravenously at 5 mL/min for 20 minutes, followed immediately by a drip-infusion of 0.02 g/kg FFM dissolved in 30 mL of saline administered over 2 hours at 0.5 mL/min. The KU Investigational Pharmacy will randomize ascorbic acid or placebo (saline) for each participant.
Study: NCT05110898
Drug: fixed-dose of olmesartan 20mg/40 mg + indapamide 1,5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose of Olmesartan 20mg or 40 mg + Indapamide 1,5 mg oral administration, once a day for 12 weeks. Initially, the participant will be treated with Olmesartan 20mg + Indapamide 1,5 mg. If after 6 weeks the diastolic blood pressure is above 90 mmHg, the dose will be changed to fixed dose of Olmesartan 40 mg + Indapamide 1,5 mg.
Study: NCT05110898
Drug: Isolated drugs Olmesartan (20 mg or 40 mg) and Indapamide (1,5 mg)
Normalized name: Indapamide
DrugBank: Indapamide (DB00808)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isolated drugs Olmesartan (20 mg or 40 mg) and Indapamide (1,5 mg) oral administration, once a day for 12 weeks. Initially, the participant will be treated with Benicar® (olmesartan) 20mg and Natrilix® (indapamide) 1,5 mg. If after 6 weeks the diastolic blood pressure is above 90 mmHg, the dose of Benicar® (olmesartan) will be changed to 40 mg.
Study: NCT04708964
Drug: Flurbiprofen
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flurbiprofen solution will be administered, through the subglottic intake door of the endotracheal tube.
Study: NCT06671470
Drug: YZJ-1139 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose 20 mg
Study: NCT06672653
Drug: The monoterpenoid zinc tetra-ascorbo-camphorate (C14)
Normalized name: C14-22 alcohols
Approvals — FDA: no, EMA: no, PMDA: no
Description: The trial phase will consist of hospital administration by vaginal syringe of 5ml of 1% C14, twice a day for 7 days, starting the first cure during the follicular phase of the cycle, just after the last menstrual period (S1), the second cure the following month (S5), the third cure 4 weeks later (S9) and the last cure 8 weeks later (S13). Gynaecological follow-up with HPV molecular testing and cervical smear will be performed two days after each course of treatment at S2, S6, S10, S14 and 2 weeks after the last course of treatment (S16). Unprotected sexual intercourse will not be permitted during each course of treatment, and for at least 72 hours before each genital swab.
Study: NCT05050630
Drug: TR2-ICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab 375 mg/m2 d0; Lenalidomide 25mg/d d1-10; Ifosfamide 5g/m2 d2; Carboplatin calculate according to AUC=5 (single dose ≤800 mg); Etoposide 100mg/m2 d1-3; Tirelizumab 200mg d6.
Study: NCT04837482
Drug: AGN-190584
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical eyedrop
Study: NCT04837482
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical eyedrop
Study: NCT06712992
Drug: SHAM Trans-spinal Direct current stimulation
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: For a sham tsDCS, the current will be ramped up for 30 seconds turned on for 5 s and then turned off in a ramp shaped fashion, thus inducing skin sensations indistinguishable from anodal tsDCS. This method was shown to achieve a good level of blinding among sessions.~These parameters for sham stimulation were chosen based on previous reports that the perceived sensations on the skin, such as tingling, fade usually out in the first 30 s of TsDcs .
Study: NCT06693375
Drug: Iron oxide nanoparticles
Normalized name: PEGylated iron oxide nanoparticles
DrugBank: MPB-1523 (DB18334)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Submucosal injection of nanoparticles in rectum, 28 mg Fe (7 mg Fe/mL)
Study: NCT06693375
Drug: Iron oxide nanoparticles
Normalized name: PEGylated iron oxide nanoparticles
DrugBank: MPB-1523 (DB18334)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Submucosal injection in rectum 56 mg Fe (3,5 mg Fe/mL)
Study: NCT06693375
Drug: Iron oxide nanoparticles
Normalized name: PEGylated iron oxide nanoparticles
DrugBank: MPB-1523 (DB18334)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Submucosal injection in rectum : 56 mg Fe (14 mg Fe/mL)
Study: NCT06693375
Drug: Iron oxide nanoparticles
Normalized name: PEGylated iron oxide nanoparticles
DrugBank: MPB-1523 (DB18334)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Submucosal injection in rectum 112 mg Fe (14 mg Fe/mL)
Study: NCT06693856
Drug: High-Dose Methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone 500mg, administered intravenously once daily for 3 consecutive days, repeated every 4 weeks for a total of 24 weeks, followed by a follow-up period.
Study: NCT06693856
Drug: Low-Dose Methylprednisolone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methylprednisolone is administered at a dose of 1mg/kg, given as an intravenous injection once daily for 3 consecutive days, repeated every 4 weeks for a total of 24 weeks, followed by a follow-up period.
Study: NCT06390982
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1000 mg/m2 orally twice daily (bid) on Day 1 to 14 of each 21-day cycle in CAPOX regimen
Study: NCT06390982
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 825 mg/m2 orally twice daily (bid) 5 days/week during radiotherapy.
Study: NCT05450601
Drug: HCP2102-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take once daily for 2 weeks orally
Study: NCT05450601
Drug: HPP2104-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drug. Take once daily for 2 weeks orally
Study: NCT05450601
Drug: HCP2102-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take once daily for 6 weeks orally
Study: NCT05450601
Drug: HPP2104-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drug. Take once daily for 6 weeks orally
Study: NCT05450601
Drug: RLD2106-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take once daily for 2 weeks orally
Study: NCT05450601
Drug: HPP2103-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drug. Take once daily for 2 weeks orally
Study: NCT05450601
Drug: RLD2106-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take once daily for 6 weeks orally
Study: NCT05450601
Drug: HPP2103-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drug. Take once daily for 6 weeks orally
Study: NCT05236673
Drug: JARDIANCE®
Approvals — FDA: no, EMA: no, PMDA: no
Description: JARDIANCE® film-coated tablets 10mg
Study: NCT06717269
Drug: NX-5948 capsule
Normalized name: Replesta NX
Approvals — FDA: no, EMA: no, PMDA: no
Description: NX-5948 in capsule form
Study: NCT05137522
Drug: Chidamide combines with VP-16 and methylprednisolone
Normalized name: etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chidamide 30mg TIW po，etoposide 100 mg/m2 was administered day1; methylprednisolone 2mg/kg days 1 to 3,then 0.75mg/kg day 4 to 6，0.25mg/kg day 7 to 9，and 0.1mg/kg day 10 to 21
Study: NCT06717269
Drug: NX-5948 tablet
Normalized name: Replesta NX
Approvals — FDA: no, EMA: no, PMDA: no
Description: NX-5948 in tablet form
Study: NCT05422612
Drug: Intervention A Fluoxetine Hydrochloride (HCl)
Normalized name: Fluoxetine Hydrochloride
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine will be administered at 10 to 60 mg daily. The initial dose for all participants will be 10 mg daily for 1 week, then increased to 20 mg daily for 2 weeks, then increased to 40 mg daily for 2 weeks, then increased to 60 mg daily for the remainder of the trial. One reduction in dose due to tolerability will be allowed. When a participant's dose is decreased due to tolerability, the dose will not be increased.
Study: NCT05422612
Drug: Intervention A Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A matching placebo will be administered at 10 to 60 mg daily in the same regimen as the intervention.
Study: NCT05422612
Drug: Intervention B Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A matching placebo will be administered at 10 to 40 mg daily in the same regimen as the intervention.
Study: NCT05422612
Drug: Intervention C Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A matching placebo will be administered at 50 mg daily in the same regimen as the intervention.
Study: NCT05422612
Drug: Intervention D Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A matching placebo will be administered via intranasal administration (one spray per nostril, per device) two times per week for the first eight weeks and then once a week for the last four weeks.
Study: NCT06708416
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets once daily
Study: NCT05635084
Drug: Placebo for YN001
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% dextrose injection to mimic the YN001
Study: NCT04855721
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06398275
Drug: NaCl 0.9%
Normalized name: DEXTROSE 5%/NACL 0.9% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl 0.9% 0.04 mL/kg
Study: NCT05336383
Drug: Radiation Therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by Infusion
Study: NCT06402760
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment methods prescribed in the guidelines.
Study: NCT04478292
Drug: mono CDDP-Group A2
Normalized name: PROCYANIDIN A2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 100 mg/m2/dose Day 1 . All non-WDF patients (A2) will receive 2 cycles of mono cisplatin (100 mg/m2/dose) chemotherapy. Each cycle lasts 3 weeks (21 days).
Study: NCT06702462
Drug: HFA-152A propellant
Normalized name: HYDROFLUOROCARBON 152A
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFA-152A propellant is administered via oral inhalation
Study: NCT06702462
Drug: HFA-134A propellant
Normalized name: HYDROFLUOROCARBON 134A
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFA-134A propellant is administered via oral inhalation
Study: NCT04478292
Drug: Consolidation (Carboplatin, Doxorubicin) -Group D1
Normalized name: PHOSPHOLIPASE D1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following Block 1-3 of induction therapy, Group D1 patients will receive 3 cycles of Carboplatin + Doxorubicin consolidation therapy. Each cycle lasts 3 weeks (21 days). Carboplatin 500 mg/m2/dose Day 1; Doxorubicin 20 mg/m2/dose Day 1 and 2; (Dexrazoxane: 200 mg/m2/dose Day 1 and 2, where is available).
Study: NCT06723652
Drug: SHR-1918 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-1918 placebo three administration+SHR-1918 three administration
Study: NCT06385964
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo by dry powder inhalation
Study: NCT06724614
Drug: VDPHL01
Approvals — FDA: no, EMA: no, PMDA: no
Description: VDPHL01 Extended Release (ER) Tablet
Study: NCT06724614
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06722417
Drug: Icalcaprant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsules
Study: NCT06723756
Drug: Treatment A: BGF MDI HFO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 2 inhalations of BGF MDI HFO (Budesonide/glycopyrronium/fomoterol fumarate pressurized inhalation suspension 160/14.4/4.8 μg per actuation) as a single dose via oral inhalation administered during 1 Treatment period.
Study: NCT06723756
Drug: Treatment B: BGF MDI HFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 2 inhalations of BGF MDI HFA (Budesonide/glycopyrronium/fomoterol fumarate pressurized inhalation suspension 160/14.4/4.8 μg per actuation) as a single dose via oral inhalation administered during 2 Treatment periods.
Study: NCT06724978
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo as an oral suspension.
Study: NCT05703282
Drug: AD-104-A
Normalized name: OLIGOPEPTIDE 104
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO, Single-Dose, AD-104-A
Study: NCT04762017
Drug: OCS-05 +SoC (corticosteroid) IV administration
Normalized name: OC 8 Adult Acne
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCS-05 + SoC (corticosteroid) IV administration for 5 consecutive days
Study: NCT06727773
Drug: Placebo medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsule
Study: NCT06726577
Drug: TP04HN106
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the treatment period, the experimental drug group received intravenous injections of 0.83mL/kg TP04HN106 each time; During the extension period, all subjects received intravenous injection of 0.83mL/kg TP04HN106.
Study: NCT06733441
Drug: TLN-254
Approvals — FDA: no, EMA: no, PMDA: no
Description: TLN-254 will be administered orally at a specified dose on specified days depending on treatment allocation.
Study: NCT06733441
Drug: TLN-254
Approvals — FDA: no, EMA: no, PMDA: no
Description: TLN-254 will be administered orally at a specified dose on specified days.
Study: NCT05628467
Drug: Antidepressive Agents
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compare the signal obtained from the pharmacovigilance database study between adults over 65 who fall on antidepressants versus those who fall on other drugs
Study: NCT06738108
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alteplase IV infusion
Study: NCT02811133
Drug: Inositol
Normalized name: Inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive inositol
Study: NCT05901714
Drug: Phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT05701436
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
Study: NCT04951648
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed (500mg/m2) plus Carboplatin (AUC5)or Pemetrexed (500mg/m2) plus Cisplatin (75mg/m2) on Day 1 of 21day cycles (every 3 weeks) for 4\~6 cycles, followed by pemetrexed mainten-ance therapy every 3 weeks until disease progress-ssion, unacceptable toxicity or other discontinuation criteria are met.
Study: NCT06692491
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil 600mg/m2,D1-5,q3w Patients with advanced rare tumours who failed to standard treatment will be administrated with fluorouracil if PDOs show the highest response to this drug under the guidance of MTB.
Study: NCT06692491
Drug: Other
Normalized name: others
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with advanced rare tumours who failed to standard treatment in RWS ICF Group will be administrated with empirical chemotherapy(e.g., Albumin-Bound Paclitaxel, Epirubicin, Gemcitabine, Vinorelbine, Cisplatin, Irinotecan, Fluorouracil), immunological(e.g., Nivolumab, Pembrolizumab, Durvalumab, Atezolizumab, Sintilimab, Tislelizumab, Camrelizumab, Toripalimab, Serplulimab,Adebrelimab,Envafolimab) or targeted drugsl(e.g., Osimertinib, Alectinib, Vemurafenib, Vemurafenib, Pyrotinib, Imatinib, Palbociclib, Savolitinib, Entrectinib)treatments.
Study: NCT05701436
Drug: Oxaliplatin, Leucovorin, fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin(130 mg per square body surface area), Leucovorin(400 mg per square body surface area), and fluorouracil(2800 mg per square body surface area) were used for monthly transhepatic arterial infusions.
Study: NCT05543343
Drug: High dose or normal dose staphylococcus albicans
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 staphylococcus albicans tablets(0.3 mg) 3 times daily or 4 staphylococcus albicans tablets(0.3 mg)+4 placebo tablets 3 times daily
Study: NCT05543343
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 placebo tablets 3 times daily
Study: NCT04558918
Drug: LNP023
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken Orally b.i.d. Dosage Supplied: 200 mg Dosage form: Hard gelatin capsule Route of Administration: Oral
Study: NCT06692452
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anthracycline antibiotic, 10, 20, 50, 100, and 200 mg vials, via intravenous (into the vein) infusion per institutional standard of care.